DOV Pharmaceutical, Inc. engages in the discovery, acquisition, development, and commercialization of drug candidates for central nervous system and cardiovascular disorders. The company’s lead product Bicifadine, which is used for treatment of chronic low back pain, is in phase-3 clinical trials. Its other products, which are in various stages of development, include Indiplon, for treatment of insomnia; DOV 21,947 and DOV 216,303 for depression; DOV 102,677 for alcohol abuse and alcoholism; and DOV Diltiazem for the treatment of angina and hypertension. DOV Pharmaceutical has agreements with Neurocrine Biosciences, Inc.; Pfizer, Inc.; and Merck & Co., Inc. The company was...